To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

May 22, 2019

Today's Rundown

Featured Story

Chugai ponies up $1B+ to combine R&D operations in Yokohama

Chugai Pharmaceuticals is shelling out ¥127.3 billion on a new R&D site in Yokohama, where it will combine the work of two long-standing research labs in nearby cities. It will start building the new facility this August.

Top Stories

Novartis' asthma triplet beats GSK's Advair in phase 2 trial

Novartis’ triple combination asthma candidate QVM149 has beaten GlaxoSmithKline’s Advair in a phase 2 trial. The study linked QVM149 to statistically significant improvements in lung function, leading Novartis to talk up its potential to improve outcomes in uncontrolled asthma. 

Amgen bids $167M to buy drug discovery shop Nuevolution

Amgen has offered $167 million to buy Nuevolution. The takeover will give Amgen control of a drug discovery platform that landed Nuevolution deals with leading companies plus a pipeline of early-stage cancer and inflammation programs.

Biotech builder ElevateBio reveals its first portfolio company: AlloVir

A week after launching with $150 million, ElevateBio is unveiling its first portfolio company: AlloVir, a biotech working on off-the-shelf cell therapies against several common viruses, including flu, respiratory syncytial virus and a type of herpes virus.

Spire Health launches COPD study with its machine-washable wearable

Using an innovative wearable, Spire Health has launched a study to develop new digital biomarkers that can predict exacerbations—and potentially hospitalizations—in patients with severe chronic obstructive pulmonary disease.

Resources

[Executive Summary] Achieving a Successful Drug Product Tech Transfer

Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent.

[Whitepaper] Choosing the Best Sterile Dosage Form for Phase I Clinical Supply Needs

Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs.

[Whitepaper] Delivering oral solid dose product to Phase I Clinic in 14 weeks

Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks.

[Whitepaper] Agile Competitive Intelligence: A 3-Step Mobile Research Strategy

What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve?

[Paid Marketplace] Accelerating DoD’s Fielding of Prototypes for Medical Countermeasures

MCS is currently seeking broad-based industry/academia collaboration on research and prototype work in technical areas related to developing medical countermeasures for the Joint Warfighter.

[Whitepaper] Now Companies Can Move Validated, Mission Critical Apps To The Cloud

Learn how the cloud can support the performance and security requirements for validated, mission-critical applications historically designed and implemented exclusively via on-premises deployment.

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events